Gary J Salamido

President and CEO

[Taxpayers Protection Alliance @Protectaxpayers]

A one-year moratorium on hyperscale data centers won’t lower demand for computing power.

It will just push investment, jobs, and tax revenue elsewhere.

[Senator Ted Budd @SenTedBuddNC]

North Carolina has the operational capacity, strategic location, & military expertise that make it ideal for missions of national importance. Hosting the Phoenix II at MCAS Cherry Point would enhance this legacy & strengthen the state’s longstanding partnership with @DeptofWar.

[NC Chamber @NCChamber]

The #NCChamberFoundation is releasing a research series examining NC's long-term infrastructure competitiveness — starting with the Wallace-to-Castle Hayne rail corridor and its potential to strengthen agricultural supply chains and connectivity to the Port of Wilmington.

Read More > https://t.co/m0auwoYEA3

[NC Chamber @NCChamber]

Nuclear verdicts — jury awards exceeding $10 million — climbed 52% nationwide in 2024. N.C. isn't immune, as a recent $101 million verdict in Henderson County demonstrates. NC Chamber Deputy General Counsel Rebekah Wilson examines the trend and what tort reform can do about it.

Read More > https://t.co/qXyW1NPJ4v

[NC Chamber @NCChamber]

Registration is open for the NC Chamber's 2026 Education & Workforce Conference, presented by @Workday. Join us in Raleigh on Tuesday, Aug. 4, for a day of practical, forward-looking workforce solutions bringing educators and business leaders together.

Register > https://t.co/MbmzgctQHV
#WorkReadyNC

[Gary J Salamido @GSalamido]

Are Nuclear Verdicts on the Rise in North Carolina, and if So, How Do We Neutralize the Threat? @NCChamber https://t.co/VlyoB85XHm

[Humacyte @humacyte]

We’re excited to be at VAM 2026 and proud to host a hands‑on/SIM Lab featuring Symvess® acellular tissue engineered vessel-tyod.

During the VAM 2026 Hands‑on/SIM Lab, participants can practice handling and implantation techniques, perform anastomosis, and apply proper clamping and procedural methods—all supported by the Humacyte team throughout the session.

SIM Lab Location: Hynes Convention Center, Second Level, Auditorium
· Thursday, June 11: 10:15 AM – 6:15 PM
· Friday, June 12: 9:30 AM – 2:00 PM

Be sure to also stop by Booth 307 to connect with the Humacyte team and continue the conversation.

Contact Us Here: https://t.co/KVIoRgmfpO
Learn more about Symvess here: https://t.co/1f77QQzkzn
PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://t.co/Eg2XmrWjCQ

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

BOXED WARNING: GRAFT FAILURE: Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are property of Humacyte Global, Inc
Other trademarks are property of their respective owners.
© 2026 Humacyte Global Inc. All Rights Reserved. US-SYM-000348

#VAM2026 #SVS #SimLab #HandsOnLearning #Symvess #VascularTrauma #Humacyte $HUMA

[Gary J Salamido @GSalamido]

Business-government collaboration helps provide healthcare coverage https://t.co/n2SzH287XV

[Gary J Salamido @GSalamido]

Business-government collaboration helps provide healthcare coverage https://t.co/n2SzH287XV

[Taxpayers Protection Alliance @Protectaxpayers]

🚨Next up in TPA’s state-by-state data center analysis: Texas.

From local restrictions to concerns over grid demand, policymakers are increasingly targeting the industry despite Texas becoming America’s data center hub because of affordable energy and pro-growth policies.

https://t.co/MBePBqHvjB

[NC Chamber @NCChamber]

NC Chamber President and CEO @GSalamido and VP of Government Affairs Jake Cashion traveled to Ireland and Northern Ireland last week to strengthen partnerships in trade, investment, innovation, and workforce development — advancing NC's growing international engagement efforts.

Read More > https://t.co/Q5wJUvVT0x
#NCCInternationalCommerce

[Senator Ted Budd @SenTedBuddNC]

North Carolina is building a workforce ready for the industries of tomorrow.

Joined @clt_alliance to discuss how embracing AI as a complement—not a replacement—for skilled labor keeps our state competitive and our economy growing.

[Humacyte @humacyte]

Join us at Booth 307 at the SVS Vascular Annual Meeting, taking place June 10–13. The Humacyte team is ready to connect, walk you through the technology, and answer your questions about Symvess, a first-in-class, universally implantable, bioengineered human vessel for extremity vascular arterial injury replacement and repair. Both our sales and medical information teams will be there to answer all your questions.

Learn more about Symvess here: https://t.co/1f77QQzkzn

PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at https://t.co/Eg2XmrWjCQ

INDICATION
SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

BOXED WARNING: GRAFT FAILURE: Loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Trademarks are property of Humacyte Global, Inc
© 2026 Humacyte Global Inc. All Rights Reserved. US-SYM-000348

#Humacyte #Innovation #Biotech #VAM2026 #SVS $HUMA
REFERENCES: 1. Symvess U.S. Prescribing Information. Durham, NC. Humacyte Global, Inc.

[Senator Ted Budd @SenTedBuddNC]

Today marks the final flight of the Marine Corps’ AV-8B Harrier at Cherry Point, North Carolina. For over 40 years, the Harrier served as the @USMC's premier close air support platform around the globe.

In a new role, the Harrier will continue to inspire the next generation of leaders about the importance of American airpower & innovation. Semper Fi.

[Taxpayers Protection Alliance @Protectaxpayers]

Price controls dressed up as “Most Favored Nation” pricing are still price controls. Importing foreign pricing schemes means fewer treatments, less innovation, and more shortages.

Patients deserve access to life-saving medicines, not policies that discourage developing them.

[NC Chamber @NCChamber]

NC Chamber Cornerstone member @AmericanAir will continue operating its Charlotte hub under a one-year lease extension while long-term negotiations continue. The CLT hub contributes more than $30 billion to NC's economy and supports nearly 150,000 jobs statewide.

Read More > https://t.co/wpHD6XFm7o

[NC Chamber @NCChamber]

When Wall Street gets involved in our courts, North Carolina families and employers pay the price. Third Party Litigation Investment increases legal costs that drive up insurance and healthcare expenses. Support H315 to protect affordability and keep North Carolina competitive.

[Triangle Business Journal @TriangleBIZJrnl]

Canes CEO is behind a major push to turn Raleigh into a sports destination. https://t.co/HqvcaJn06s

[NC Chamber @NCChamber]

🚨 Today, the NC Chamber issued a Key Vote Alert urging members of the North Carolina Senate to support House Bill 315 to ban Third-Party Litigation Investment in North Carolina.

Read More > https://t.co/SmC3vg0k9g
#ncga #ncpol

[NC Chamber @NCChamber]

Global market pressures and geopolitical instability are creating real challenges for NC farmers. @CarolinaJournal spotlighted insights from a recent NC Chamber Ag Allies webinar featuring @Fertilizer_Inst President and CEO @CoreyRosenbusch on fertilizer supply chain trends shaping conditions for NC agriculture.

Read More > https://t.co/6d5ywP7rjZ